BR112013011249A2 - ibat inhibitors for treatment of metabolic disorders and related conditions - Google Patents

ibat inhibitors for treatment of metabolic disorders and related conditions

Info

Publication number
BR112013011249A2
BR112013011249A2 BR112013011249A BR112013011249A BR112013011249A2 BR 112013011249 A2 BR112013011249 A2 BR 112013011249A2 BR 112013011249 A BR112013011249 A BR 112013011249A BR 112013011249 A BR112013011249 A BR 112013011249A BR 112013011249 A2 BR112013011249 A2 BR 112013011249A2
Authority
BR
Brazil
Prior art keywords
treatment
ibat inhibitors
related conditions
metabolic disorders
disorder
Prior art date
Application number
BR112013011249A
Other languages
Portuguese (pt)
Inventor
Lindqvist Ann-Margret
Angelin Bo
Graffner Hans
Starke Ingemar
Gillberg Per-Göran
Original Assignee
Albireo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albireo Ab filed Critical Albireo Ab
Publication of BR112013011249A2 publication Critical patent/BR112013011249A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings

Abstract

inibidores de ibat para tratamento de distúrbios metabólicos e condições relacionadas. a presente invenção refere-se a certos inibidores de ibat, para a profilaxia ou tratamento de uma síndrome metabólica, obesidade, um distúrbio de metabolismo de ácido graxo, um distúrbio de utilização de glicose, ou um distúrbio em que a resistência a insulina está envolvida, tal como, diabetes melito tipo 1 ou diabetes tipo 2.ibat inhibitors for treatment of metabolic disorders and related conditions. The present invention relates to certain ibat inhibitors for the prophylaxis or treatment of a metabolic syndrome, obesity, a fatty acid metabolism disorder, a glucose utilization disorder, or a disorder in which insulin resistance is involved. , such as type 1 diabetes mellitus or type 2 diabetes.

BR112013011249A 2010-11-08 2011-11-08 ibat inhibitors for treatment of metabolic disorders and related conditions BR112013011249A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41096310P 2010-11-08 2010-11-08
SE1051166 2010-11-08
PCT/SE2011/051337 WO2012064268A1 (en) 2010-11-08 2011-11-08 Ibat inhibitors for treatment of metabolic disorders and related conditions

Publications (1)

Publication Number Publication Date
BR112013011249A2 true BR112013011249A2 (en) 2017-11-14

Family

ID=46051624

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011249A BR112013011249A2 (en) 2010-11-08 2011-11-08 ibat inhibitors for treatment of metabolic disorders and related conditions

Country Status (11)

Country Link
EP (1) EP2637667A4 (en)
JP (1) JP2013542953A (en)
KR (1) KR20130132846A (en)
CN (1) CN103221051A (en)
AU (1) AU2011326873B2 (en)
BR (1) BR112013011249A2 (en)
CA (1) CA2815941A1 (en)
MX (1) MX2013005110A (en)
MY (1) MY176863A (en)
SG (1) SG189470A1 (en)
WO (1) WO2012064268A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (en) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibitors of the recycling of bile acids and satiogens for the treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
MX345040B (en) * 2010-11-08 2017-01-16 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder.
HUE030062T2 (en) 2010-11-08 2017-04-28 Albireo Ab Ibat inhibitors for the treatment of liver diseases
US20140243281A1 (en) 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
KR102296314B1 (en) * 2014-06-25 2021-09-01 이에이 파마 가부시키가이샤 Solid preparation and method for stabilizing same
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
KR101719321B1 (en) * 2016-03-31 2017-03-23 충남대학교산학협력단 Composition for treating obesity or depressive disorder comprising 3-(4-chlorophenyl)benzo[4,5]imidazo[2,1-b]thiazole-6-carboxylic acid
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (en) 2018-06-05 2023-06-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
AU2019290337B2 (en) 2018-06-20 2023-01-12 Albireo Ab Crystal modifications of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761018A (en) 2019-12-04 2022-07-15 阿尔比里奥公司 Benzothiadiazepine compounds and their use as bile acid modulators
CR20220315A (en) 2019-12-04 2022-10-26 Albireo Ab BENZOTI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
JP2023537285A (en) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
KR20230117393A (en) 2020-12-04 2023-08-08 알비레오 에이비 Benzothia(di)azepine compounds and their use as bile acid regulators
WO2022166680A1 (en) * 2021-06-25 2022-08-11 苏州科睿思制药有限公司 Crystal form of odevixibat, and preparation method and use therefor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
NZ531796A (en) * 2001-09-08 2005-10-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
WO2004020421A1 (en) * 2002-08-28 2004-03-11 Asahi Kasei Pharma Corporation Novel quaternary ammonium compounds
EP2102201B1 (en) * 2006-12-11 2010-10-13 Merck Sharp & Dohme Corp. Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
JP2010006707A (en) * 2008-06-24 2010-01-14 Daiichi Sankyo Co Ltd Medicine containing thiazepine derivative
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
US20110319396A1 (en) * 2009-01-23 2011-12-29 Msd K.K. Benzodiazepin-2-on derivatives
MX345040B (en) * 2010-11-08 2017-01-16 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder.

Also Published As

Publication number Publication date
CA2815941A1 (en) 2012-05-18
WO2012064268A1 (en) 2012-05-18
SG189470A1 (en) 2013-05-31
JP2013542953A (en) 2013-11-28
EP2637667A1 (en) 2013-09-18
MY176863A (en) 2020-08-24
CN103221051A (en) 2013-07-24
EP2637667A4 (en) 2014-06-25
AU2011326873B2 (en) 2015-02-19
KR20130132846A (en) 2013-12-05
AU2011326873A1 (en) 2013-04-11
MX2013005110A (en) 2013-08-21

Similar Documents

Publication Publication Date Title
BR112013011249A2 (en) ibat inhibitors for treatment of metabolic disorders and related conditions
EP2621282A4 (en) Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
GT201300215A (en) GLUCOSILCERAMIDE SINTASA INHIBITORS
MX2015008114A (en) Exendin-4 Derivatives.
HRP20170209T1 (en) Lixisenatide as add-on therapy to basal insulin in type 2 diabetes
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
WO2013052965A3 (en) Control of whole body energy homeostasis by microrna regulation
BR112012027915A2 (en) Nitro fatty acids - Neuroprotection and / or inhibition of cognitive decline
MX344925B (en) Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders.
BR112014012398A2 (en) performance and power management computing with firmware performance data structure
ECSP13012661A (en) PHARMACEUTICAL COMPOSITION, TREATMENT METHODS AND USES OF THE SAME.
GT201200293A (en) USEFUL PREDICTIVE MARKERS IN THE TREATMENT OF FRAGILE SYNDROME X (FXS)
GT201100118A (en) ARILO COMPOUNDS WITH HETEROCYCLIC SUBSTITUTES AS HIF INHIBITORS
MX2014015423A (en) Exendin-4 peptide analogues.
ITTO20110627A1 (en) PHARMACEUTICAL COMPOSITION OF COMBINATION AND METHODS TO TREAT DIABETES AND METABOLIC DISORDERS
BR112013029256A8 (en) pharmaceutical combination for use in treating patients with type 2 diabetes
BR112014004726A2 (en) pharmaceutical combination for use in glycemic control in type 2 diabetes patients
BR112014006587A8 (en) COMPOUND COMPRISING OLIGONUCLEOTIDE THAT MODULATES GCGR EXPRESSION, COMPOSITION, AS WELL AS ITS USE IN THE TREATMENT OR PREVENTION OF DIABETES
BR112013029062A2 (en) lixisenatide and metformin for the treatment of type 2 diabetes
MX349254B (en) Compounds for treatment of metabolic syndrome.
BR112012031873A2 (en) ccr2 cyclohexyl azetidinyl antagonists
GB201101459D0 (en) Novel compounds and thier effects on fedding behaviour
BR112012005044B8 (en) pharmaceutical composition comprising a combination of (rac)-tramadol·hcl and celecoxib
BR112012018703A2 (en) compounds and their effects on eating behavior
CR20140473A (en) PIRAZOL COMPOUNDS AS SGLT1 INHIBITORS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2487 DE 04-09-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]